Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,longTermDebt,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,repurchaseOfStock,capitalExpenditures,WC,language,region,quoteType,triggerable,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Feb 11, 2021) 4","Short Ratio (Feb 11, 2021) 4","Short % of Float (Feb 11, 2021) 4","Short % of Shares Outstanding (Feb 11, 2021) 4","Shares Short (prior month Jan 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,IDXG,-51567000.0,4112840,637000,,-4138000,,-4207000,5330000,4517000,-2562000,-2562000,,-135000,,,,15000,9833000,12395000,5316000,-1576000,-54000,-4153000,-4207000,10238000.0,184798000.0,30218000.0,-32896000.0,4217000.0,43858000.0,402000.0,788000.0,-216323000.0,6320000.0,8433000.0,-1773000.0,42000.0,2839000.0,20461000.0,10880000.0,14265000.0,7851000.0,2227000.0,3008000.0,,-1534000.0,39000.0,5000000.0,5034000.0,-1520000.0,108000.0,67000.0,-5006000.0,1532000.0,317000.0,-74000.0,354000.0,,,-6196000.0,en-US,US,EQUITY,False,USD,us_market,"Interpace Biosciences, Inc.",False,False,PNK,8.75,1630526170,-0.25,9.1,9.1,8.72,5772,PRE,0,2,-2.777778,8.72 - 9.1,9.0,0.0,0.0,8,8,finmb_383855,"Interpace Biosciences, Inc.",Other OTC,USD,9097,4624,6.1779003,2.4018898,2.5721 - 10.51,-1.7600002,-0.16745958,2.5721,10.51,1579046400,1620751628,1620751628,1620751628,-5.968,0.6,-2.51,-3.4860559,-7.998,8.888611,-0.13861084,-0.015594208,7.937364,0.8126359,0.10238108,35987352,14.583333,-1.0940235,15,America/New_York,EDT,-14400000,1.26,,,10.51,2.57,8.89,7.94,9.1k,4.62k,4.11M,,3.43M,26.70%,0.32%,47.35k,0.19,1.18%,1.17%,68.56k,,,,,,0.00%,"Jan 14, 2020",,1:10,"Jan 14, 2020","Dec 30, 2020","Mar 30, 2021",-72.84%,-68.80%,-23.31%,-71.40%,33.17M,8.19,8.50%,10.72M,-17.21M,-23.93M,-5.97,,2.84M,0.69,9.57M,70.19,0.70,-8.00,-11.86M,-4.96M,Value,07054,Healthcare,152,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",Parsippany,855 776 6419,NJ,1609372800,United States,http://www.interpace.com,86400,Morris Corporate Center 1,973 265 0191,Diagnostics & Research,Building C 300 Interpace Parkway
t-1,IDXG,-48867000.0,4112840,672000,,-8077000,,-8143000,9767000,3129000,-8425000,-8425000,,-135000,,,,10000,9646000,18071000,6517000,348000,-56000,-8087000,-8143000,11351000.0,184404000.0,28228000.0,-29083000.0,4183000.0,45681000.0,402000.0,645000.0,-212116000.0,6317000.0,8433000.0,-1773000.0,42000.0,2772000.0,18233000.0,11733000.0,14122000.0,8028000.0,2052000.0,4511000.0,,1121000.0,-300000.0,5000000.0,-52000.0,3022000.0,108000.0,-1936000.0,-1584000.0,1299000.0,100000.0,-74000.0,917000.0,-52000.0,-300000.0,-4111000.0,en-US,US,EQUITY,False,USD,us_market,"Interpace Biosciences, Inc.",False,False,PNK,8.75,1630526170,-0.25,9.1,9.1,8.72,5772,PRE,0,2,-2.777778,8.72 - 9.1,9.0,0.0,0.0,8,8,finmb_383855,"Interpace Biosciences, Inc.",Other OTC,USD,9097,4624,6.1779003,2.4018898,2.5721 - 10.51,-1.7600002,-0.16745958,2.5721,10.51,1579046400,1620751628,1620751628,1620751628,-5.968,0.6,-2.51,-3.4860559,-7.998,8.888611,-0.13861084,-0.015594208,7.937364,0.8126359,0.10238108,35987352,14.583333,-1.0940235,15,America/New_York,EDT,-14400000,1.26,,,10.51,2.57,8.89,7.94,9.1k,4.62k,4.11M,,3.43M,26.70%,0.32%,47.35k,0.19,1.18%,1.17%,68.56k,,,,,,0.00%,"Jan 14, 2020",,1:10,"Jan 14, 2020","Dec 30, 2020","Mar 30, 2021",-72.84%,-68.80%,-23.31%,-71.40%,33.17M,8.19,8.50%,10.72M,-17.21M,-23.93M,-5.97,,2.84M,0.69,9.57M,70.19,0.70,-8.00,-11.86M,-4.96M,Value,07054,Healthcare,152,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",Parsippany,855 776 6419,NJ,1609372800,United States,http://www.interpace.com,86400,Morris Corporate Center 1,973 265 0191,Diagnostics & Research,Building C 300 Interpace Parkway
t-2,IDXG,-42735000.0,4112840,763000,,-6155000,,-6234000,7181000,3054000,-6005000,-6005000,,-138000,,,,14000,8248000,14253000,5194000,-150000,-65000,-6169000,-6234000,12504000.0,183543000.0,25963000.0,-21798000.0,4443000.0,50701000.0,402000.0,424000.0,-203973000.0,6583000.0,8433000.0,-1770000.0,42000.0,5308000.0,15601000.0,12090000.0,17632000.0,8988000.0,2423000.0,3390000.0,,42000.0,-362000.0,-3400000.0,-3714000.0,768000.0,108000.0,-9798000.0,-5722000.0,1394000.0,-1224000.0,-74000.0,-468000.0,-52000.0,-362000.0,2031000.0,en-US,US,EQUITY,False,USD,us_market,"Interpace Biosciences, Inc.",False,False,PNK,8.75,1630526170,-0.25,9.1,9.1,8.72,5772,PRE,0,2,-2.777778,8.72 - 9.1,9.0,0.0,0.0,8,8,finmb_383855,"Interpace Biosciences, Inc.",Other OTC,USD,9097,4624,6.1779003,2.4018898,2.5721 - 10.51,-1.7600002,-0.16745958,2.5721,10.51,1579046400,1620751628,1620751628,1620751628,-5.968,0.6,-2.51,-3.4860559,-7.998,8.888611,-0.13861084,-0.015594208,7.937364,0.8126359,0.10238108,35987352,14.583333,-1.0940235,15,America/New_York,EDT,-14400000,1.26,,,10.51,2.57,8.89,7.94,9.1k,4.62k,4.11M,,3.43M,26.70%,0.32%,47.35k,0.19,1.18%,1.17%,68.56k,,,,,,0.00%,"Jan 14, 2020",,1:10,"Jan 14, 2020","Dec 30, 2020","Mar 30, 2021",-72.84%,-68.80%,-23.31%,-71.40%,33.17M,8.19,8.50%,10.72M,-17.21M,-23.93M,-5.97,,2.84M,0.69,9.57M,70.19,0.70,-8.00,-11.86M,-4.96M,Value,07054,Healthcare,152,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",Parsippany,855 776 6419,NJ,1609372800,United States,http://www.interpace.com,86400,Morris Corporate Center 1,973 265 0191,Diagnostics & Research,Building C 300 Interpace Parkway
t-3,IDXG,-38179000.0,4112840,550000,,-5501000,,-5580000,5703000,1396000,-5972000,-5972000,,-167000,,,,13000,5446000,11418000,4050000,471000,-66000,-5514000,-5580000,13619000.0,182980000.0,30202000.0,-16127000.0,4571000.0,60611000.0,402000.0,167000.0,-197739000.0,6707000.0,8433000.0,-1770000.0,42000.0,15106000.0,16098000.0,12421000.0,26096000.0,7764000.0,2331000.0,3348000.0,3400000.0,-1005000.0,-913000.0,2200000.0,2200000.0,2547000.0,108000.0,1736000.0,449000.0,1473000.0,2701000.0,-74000.0,544000.0,-52000.0,-913000.0,9998000.0,en-US,US,EQUITY,False,USD,us_market,"Interpace Biosciences, Inc.",False,False,PNK,8.75,1630526170,-0.25,9.1,9.1,8.72,5772,PRE,0,2,-2.777778,8.72 - 9.1,9.0,0.0,0.0,8,8,finmb_383855,"Interpace Biosciences, Inc.",Other OTC,USD,9097,4624,6.1779003,2.4018898,2.5721 - 10.51,-1.7600002,-0.16745958,2.5721,10.51,1579046400,1620751628,1620751628,1620751628,-5.968,0.6,-2.51,-3.4860559,-7.998,8.888611,-0.13861084,-0.015594208,7.937364,0.8126359,0.10238108,35987352,14.583333,-1.0940235,15,America/New_York,EDT,-14400000,1.26,,,10.51,2.57,8.89,7.94,9.1k,4.62k,4.11M,,3.43M,26.70%,0.32%,47.35k,0.19,1.18%,1.17%,68.56k,,,,,,0.00%,"Jan 14, 2020",,1:10,"Jan 14, 2020","Dec 30, 2020","Mar 30, 2021",-72.84%,-68.80%,-23.31%,-71.40%,33.17M,8.19,8.50%,10.72M,-17.21M,-23.93M,-5.97,,2.84M,0.69,9.57M,70.19,0.70,-8.00,-11.86M,-4.96M,Value,07054,Healthcare,152,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",Parsippany,855 776 6419,NJ,1609372800,United States,http://www.interpace.com,86400,Morris Corporate Center 1,973 265 0191,Diagnostics & Research,Building C 300 Interpace Parkway
